[BMRN] BioMarin Pharmaceutical Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 85.66 Change: 2.12 (2.54%)
Ext. hours: Change: 0 (0%)

chart BMRN

Refresh chart

Strongest Trends Summary For BMRN

BMRN is in the medium-term down -30% below S&P in 2 years. In the long-term up 774% in 25 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Ph

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.02 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 5.98% Sales Growth - Q/Q-11.95% P/E-86.75
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-4.46% ROE-6.74% ROI-5.17%
Current Ratio4.98 Quick Ratio4.25 Long Term Debt/Equity0.54 Debt Ratio0.13
Gross Margin82.59% Operating Margin-16.48% Net Profit Margin-20.35% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities914.79 M Cash From Investing Activities-750.87 M Cash From Operating Activities-137.81 M Gross Profit170.45 M
Net Profit-67.5 M Operating Profit-66.02 M Total Assets3.66 B Total Current Assets1.52 B
Total Current Liabilities305.51 M Total Debt655.49 M Total Liabilities1.23 B Total Revenue203.26 M
Technical Data
High 52 week106.07 Low 52 week76.01 Last close76.99 Last change0.13%
RSI33.73 Average true range2.22 Beta1.08 Volume685.95 K
Simple moving average 20 days-3.78% Simple moving average 50 days-6.13% Simple moving average 200 days-13.32%
Performance Data
Performance Week-1.09% Performance Month-6.93% Performance Quart-6.6% Performance Half-18.34%
Performance Year-25.48% Performance Year-to-date-9.58% Volatility daily1.48% Volatility weekly3.31%
Volatility monthly6.78% Volatility yearly23.47% Relative Volume211.9% Average Volume1.29 M
New High New Low

News

2020-05-27 15:03:06 | Hedge Funds Have Never Been More Bullish On BioMarin Pharmaceutical Inc. BMRN

2020-05-27 12:55:00 | Stocks To Watch: BioMarin Pharmaceutical Sees RS Rating Rise To 91

2020-05-27 10:35:00 | What Sanofi Might Buy With Its Regeneron Windfall

2020-05-19 16:15:00 | BioMarin Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $50 million of 1.25% Senior Subordinated Convertible Notes due 2027

2020-05-13 16:38:00 | New Convertible-Bond Issues at 12-Year Highs. What’s in It for Investors.

2020-05-11 23:26:00 | BioMarin Announces Pricing of Upsized $550 Million Senior Subordinated Convertible Notes Offering

2020-05-11 07:16:00 | BioMarin Announces Proposed Private Offering of $500 Million of Senior Subordinated Convertible Notes

2020-05-08 11:23:17 | 5 Biopharmas Where BofA Would Put Its Money To Work

2020-05-06 08:30:00 | BioMarin to Participate in Two Upcoming Virtual Investor Conferences

2020-05-04 15:12:59 | Trump expresses confidence for coronavirus vaccine ‘by the end of the year’

2020-05-04 10:43:10 | BioMarin Strikes Gene Therapy Partnership Targeting Rare Genetic Cardiomyopathies

2020-05-04 02:35:35 | BioMarin Teams Up With DiNAQOR On Rare Heart Disease Gene Therapies

2020-05-03 16:01:00 | BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies

2020-05-01 18:26:12 | Top 5 Buys of David Carlson's Elfun Trusts in the 1st Quarter

2020-05-01 06:52:08 | BioMarin Pharmaceutical Inc.'s NASDAQ:BMRN Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

2020-04-30 09:47:01 | BioMarin BMRN Beats on Q1 Earnings, Lowers Sales View

2020-04-30 06:54:00 | BioMarin Blows Past Q1 Estimates, Projects 1st Year of Profitability in 2020

2020-04-30 03:05:24 | Edited Transcript of BMRN earnings conference call or presentation 29-Apr-20 8:15pm GMT

2020-04-30 02:31:02 | Biomarin Pharmaceutical Inc BMRN Q1 2020 Earnings Call Transcript

2020-04-29 17:45:09 | BioMarin Pharmaceutical BMRN Tops Q1 Earnings and Revenue Estimates

2020-04-29 16:01:00 | BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million

2020-04-22 16:30:00 | BioMarin Updates Timing of First Quarter 2020 Financial Results Conference Call and Webcast to Wednesday, April 29 at 4:15pm ET

2020-04-21 08:31:00 | BioMarin Appoints Global Pharmaceutical Veteran C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations, Effective May 4

2020-04-17 07:00:10 | uniQure Announces the Nomination of Leonard E. Post, Ph.D. to its Board of Directors

2020-04-14 08:30:00 | BioMarin to Host First Quarter 2020 Financial Results Conference Call and Webcast on Thursday, April 30 at 4:30pm ET

2020-04-07 11:04:03 | Biomarin to File Regulatory Applications for Vosoritide in Q3

2020-04-06 08:31:00 | BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe

2020-03-27 11:30:03 | BioMarin BMRN Down 8% Since Last Earnings Report: Can It Rebound?

2020-03-11 19:09:35 | Is BioMarin Pharmaceutical Inc. BMRN Going to Burn These Hedge Funds?

2020-03-09 15:10:00 | BioMarin's Brinda Balakrishnan, M.D., Ph.D., Honored with 2020 "40 Under 40" Award from the San Francisco Business Times

2020-03-04 07:18:26 | An Intrinsic Calculation For BioMarin Pharmaceutical Inc. NASDAQ:BMRN Suggests It's 26% Undervalued

2020-02-27 10:38:03 | BioMarin BMRN Q4 Earnings Beat, Sales Miss, Valrox in Focus

2020-02-27 10:06:03 | Stock Market News for Feb 27, 2020

2020-02-27 03:10:19 | Edited Transcript of BMRN earnings conference call or presentation 26-Feb-20 9:30pm GMT

2020-02-26 17:35:10 | BioMarin Pharmaceutical BMRN Q4 Earnings Top Estimates

2020-02-26 05:00:00 | Biomarin- Gene Therapy and Hemophilia

2020-02-24 09:28:02 | BioMarin BMRN to Report Q4 Earnings: What's in the Cards?

2020-02-24 08:59:01 | BioMarin BMRN Catches Eye: Stock Jumps 6.1%

2020-02-21 07:46:22 | The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion

2020-02-20 16:05:00 | BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020

2020-02-19 12:31:05 | BioMarin Pharmaceutical BMRN Earnings Expected to Grow: Should You Buy?

2020-02-18 17:22:42 | Frank Sands' Firm Sells 4 Stocks in 4th Quarter

2020-02-18 13:19:00 | Health-care stocks hinge on presidential politics — and they’re now looking favorable

2020-02-12 08:30:00 | BioMarin to Participate in Two Upcoming Investor Conferences

2020-02-11 17:54:16 | Drug makers tap genetic test to save kids with seizures

2020-02-04 17:29:58 | Goldman Sachs Sets BioMarin Target 75% Above Current Price

2020-02-04 07:51:48 | The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares

2020-02-03 16:30:00 | BioMarin Announces CFO Succession

2020-02-03 11:27:34 | Andreas Halvorsen Trims Adaptive Biotechnologies Stake

2020-01-29 08:30:00 | BioMarin to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Wednesday, February 26 at 4:30pm ET